BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office Of The Chief Scientist
Published: Dec 23, 2013
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product in development by Cell Cure for the treatment of age-related macular degeneration. Cell Cure’s plans for the development of OpRegen® include completion of preclinical testing and filing an IND application to commence human clinical trials in 2014.
Help employers find you! Check out all the jobs and post your resume.